Adagene Inc. (ADAG) |
|
1.53 0.06 (4.08%)
|
09-29 09:37 |
|
Open: |
1.53 |
Pre. Close: |
1.47 |
|
High:
|
1.53 |
Low:
|
1.53 |
|
Volume:
|
991 |
Market Cap:
|
67(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:25:40 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.82 One year: 2.12 |
| Support: |
Support1: 1.27 Support2: 1.1 |
| Resistance: |
Resistance1: 1.55 Resistance2: 1.82 |
| Pivot: |
1.4 |
| Moving Average: |
MA(5): 1.43 MA(20): 1.39
MA(100): 1.36 MA(250): 1.39 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 86.8 %D(3): 69.4 |
| RSI: |
RSI(14): 61.6 |
| 52-week: |
High: 2.09 Low: 0.89 |
| Average Vol(K): |
3-Month: 12 (K) 10-Days: 7 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ADAG ] has closed below upper band by 5.6%. Bollinger Bands are 6.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.53 - 1.54 |
1.54 - 1.55 |
|
Low:
|
1.51 - 1.52 |
1.52 - 1.53 |
|
Close:
|
1.52 - 1.53 |
1.53 - 1.54 |
|
Company Description |
|
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China. |
Headline News |
Wed, 27 Sep 2023
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Nasdaq
Fri, 08 Sep 2023
天演藥業（Adagene Inc., NASDAQ：ADAG）宣佈將於九月出席多個 ... - 新浪香港
Thu, 07 Sep 2023
Adagene to Present at Investor and Scientific Conferences in ... - BioSpace
Thu, 31 Aug 2023
Adagene Reports Six Month Financial Results for 2023 and ... - GlobeNewswire
Wed, 05 Jul 2023
Healthcare Stocks Making Moves Wednesday: IMPL, ALLR, CBUS, IMUX, XXII, SAVA, BTCY, ADAG - InvestorsObserver
Thu, 04 May 2023
Adagene Achieves $3 Million Milestone in Collaboration with ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
44 (M) |
| Shares Float |
17 (M) |
|
% Held by Insiders
|
10.5 (%) |
|
% Held by Institutions
|
9.5 (%) |
|
Shares Short
|
29 (K) |
|
Shares Short P.Month
|
20 (K) |
Stock Financials |
|
EPS
|
-0.8 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.88 |
|
Profit Margin (%)
|
-160.8 |
|
Operating Margin (%)
|
-180.5 |
|
Return on Assets (ttm)
|
-16.3 |
|
Return on Equity (ttm)
|
-37.3 |
|
Qtrly Rev. Growth
|
340.8 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.51 |
|
EBITDA (p.s.)
|
-0.9 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-1.94 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.8 |
|
Price to Sales
|
2.95 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
